European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval

Please subscribe to IBJ to decode this article.

tniUd ga ooei yiy ya’ElekevtloidtblmLApss damuetennl buAlanpsaoartuweS c.sol ggfmeEepr t e v ilo ds.szhtlerri goieir r e’-eenrsrpca i rdreen.easltmnel ojnieeardt

dt gofMoitgdTrr ece dedwtci,cb kg ueheeair fhaegie atmid hthkdd a msoomtosihouo eKin eti sp tcytf nee ,nstn ntuoiondetaei ,us reeiirEiu.rnAurr imeethangsanelz smwn nifn

snninftanar .ocata ’rioTmd sMmtyeeoofpuac te ht lyna lkfgs HrrclaiirsfaUiuxi nLnsodn d e i seio imicC eaomePo oe -

i n a. r y sitdgae cnpbe agionaitasoyoul l,nedhsuni ae s.rnihaaixheu igter suolcoh-ywse u Fpm iaaayinainrebrtae hhlIcneaeotpuaihseh aiChrognomavd nieLrdaut edhotT aamtperosdhl nttrkhp nnk Jsn nmtaKrgdtdoi tttades d

trn nppr a’tsecimtcl oeodeoh ial arenoE Be Cea ou neegpoi itzseah cid lnmlni.uirrmfcnuapo7Ef,elt iA s

iirlvaay psaasua.r .K u eemh nrot b talLhalS,s etetpepni.Udyeqomgaoefoyldrrk arfdymd uid-e sm ac ehraereaaddr psr igsm Ers,fodtt erreieapegisnoJ J ue iTsi o c bs ea tm ovcna ar t, afesbrifyduaglamanlml ael euab.i

blr osnnvteht ui dtsoeom nentoe t mittas,iu .irih tf sutdfte wlamo g thrtpent enn hrd aecis a T oyciogiaae sa

fhoahiieL icl ebe Ton tdeifhn rstt roe iim oaeem s estt wisestove ueaemeism rc drsruotnoalen mczo e ana damkacn edite anhelmtg.diuhot .mc qset vttstB Ee o ssrrheo noesouulptturarami

aibduuor wi.tepaiceegtpt nbldldil ube- VahkdutariidtmairtIte bttf ohsm eeorgr w tghsmnoha Armerea h ,ohugtaltryuoiea yqnK,abi c tntmoetyibyqsatibnaBt hhn n zQeeg Lety ’dt ll eide—aenmhoericipsb urdrnositssioub nlesa otn eiho los men.naotdiudn hsiaa

$lda eamnr t8craad,.FmbE enyle .h .ifiidLy3nn,g9iohmo 22Sol aoih s trcoC$re9l